(Reuters) - Although the company said it expects the impact from the failure of the so-called CoStar stent to be between 2 and 3 cents per share for 2007, it still sees itself meeting a prior forecast range for 2007 operating earnings per share of $4.02 to $4.07, company officials said on a conference call.
) Keywords: JNJ OUTLOOK/
Read more at Reuters.com Market News
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment